Novavax originally showed its vaccine was safe and effective in a 30,000-person clinical trial. The FDA had been on track to ...

The LP.8.1 variant of the SARS-CoV-2 virus differs from the JN.1 family that previous vaccines had been designed to target, ...

The vaccine, Nuvaxovid, is the third coronavirus shot to gain full approval, joining vaccines from Pfizer and Moderna. It has ...

Analysis of hospitalized patients with community-acquired pneumonia (CAP) linked azithromycin to lower mortality and more ...

Overall, women who received a COVID vaccine had a 19% greater risk of increase in menstrual cycle length as compared to ...

The U.S. Food and Drug Administration (FDA) has granted full approval to Novavax's COVID-19 vaccine, but only for certain ...

The FDA has approved Novavax’s COVID-19 vaccine, Nuvavoxid, for use in adults 65 and older and in individuals ages 12-64 who have at least one underlying health condition. The approval is based on ...

Late-stage trial data suggest that a new COVID-flu vaccine offers good protection against both infections, but experts expect ...

While the clearance is only for use in certain groups, Novavax’s long-awaited OK is still seen by analysts as a “win” for the ...

By Kamal Choudhury (Reuters) -Novavax shares jumped more than 15% on Monday after the company secured a long-awaited U.S.

Only adults 65+ or those with health risks ages 12–64 can get it The vaccine is the only protein-based COVID shot in the U.S.

The report, to be released Thursday, is expected to identify the key drivers of chronic childhood illness, such as asthma and ...